1
|
Sadaf T, John P, Bhatti A, Malik JM. Lack of association of -863C/A (rs1800630) polymorphism of tumor necrosis factor-a gene with rheumatoid arthritis. Arch Med Sci 2019; 15:531-536. [PMID: 30899307 PMCID: PMC6425217 DOI: 10.5114/aoms.2018.76946] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Accepted: 02/02/2017] [Indexed: 12/14/2022] Open
Abstract
INTRODUCTION Multifunctional pro-inflammatory cytokine tumor necrosis factor-α (TNF-α) has been implicated in a variety of inflammatory diseases including rheumatoid arthritis (RA). TNF-α polymorphisms are mostly located in its promoter region and play a significant role in disease susceptibility and severity. We therefore sought to investigate TNFA -863C/A (rs1800630) polymorphism association with RA activity in our Pakistani study group. MATERIAL AND METHODS A total of 268 human subjects were enrolled. Among them, 134 were RA patients and 134 were controls. In this study the physical parameters of RA patients were collected, and the disease activity was measured by DAS28. The genotypes were determined following the allele-specific PCR along with the pre-requisite internal amplification controls. Subsequently, data were analyzed statistically for any significant association including χ2/Fisher's exact test using GraphPad prism 6 software. RESULTS We found that the TNF-α -863 C/A (rs1800630) variant was not differentially segregated between cases and controls in either genotype frequency, with χ2 of 2.771 and a p-value of 0.2502, or allele frequency, with χ2 of 2.741 and a p-value of 0.0978, with an odds ratio (95% CI) of 0.7490 (0.5317-1.055). CONCLUSIONS The lack of positive association of TNF-α -863(rs1800630) polymorphism in our study group implies that TNF-α -863 polymorphism is not a susceptible marker to RA and cannot serve as a genetic factor for screening RA patients in Pakistan. There might be other factors that may influence disease susceptibility. However, further investigations on additional larger and multi-regional population samples are required to determine the consequences of genetic variations for disease prognosis.
Collapse
Affiliation(s)
- Tayyaba Sadaf
- Department of Health Care Biotechnology, Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Islamabad, Pakistan
| | - Peter John
- Department of Health Care Biotechnology, Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Islamabad, Pakistan
| | - Attya Bhatti
- Department of Health Care Biotechnology, Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Islamabad, Pakistan
| | - Javaid M. Malik
- Arthritis Research Center, Rahmat Noor Clinic, Rawalpindi, Pakistan
| |
Collapse
|
2
|
Vignal CM, Bansal AT, Balding DJ. Using Penalised Logistic Regression to Fine Map HLA Variants for Rheumatoid Arthritis. Ann Hum Genet 2011; 75:655-64. [DOI: 10.1111/j.1469-1809.2011.00670.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
3
|
Epidemiología genética de la artritis reumatoide: ¿qué esperar de América Latina? BIOMEDICA 2011. [DOI: 10.7705/biomedica.v26i4.326] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
4
|
Okada Y, Yamada R, Suzuki A, Kochi Y, Shimane K, Myouzen K, Kubo M, Nakamura Y, Yamamoto K. Contribution of a haplotype in the HLA region to antiâcyclic citrullinated peptide antibody positivity in rheumatoid arthritis, independently of HLAâDRB1. ACTA ACUST UNITED AC 2009; 60:3582-90. [DOI: 10.1002/art.24939] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
5
|
|
6
|
Recent progress in rheumatoid arthritis genetics: one step towards improved patient care. Curr Opin Rheumatol 2009; 21:262-71. [DOI: 10.1097/bor.0b013e32832a2e2d] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
7
|
Harney SMJ, Vilariño-Güell C, Adamopoulos IE, Sims AM, Lawrence RW, Cardon LR, Newton JL, Meisel C, Pointon JJ, Darke C, Athanasou N, Wordsworth BP, Brown MA. Fine mapping of the MHC Class III region demonstrates association of AIF1 and rheumatoid arthritis. Rheumatology (Oxford) 2008; 47:1761-7. [PMID: 18835879 DOI: 10.1093/rheumatology/ken376] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVES The heritability of RA has been estimated to be approximately 55%, of which the MHC contributes about one-third. HLA-DRB1 alleles are strongly associated with RA, but it is likely that significant non-DRB1 MHC genetic susceptibility factors are involved. Previously, we identified two three-marker haplotypes in a 106-kb region in the MHC class III region immediately centromeric to TNF, which are strongly associated with RA on HLA-DRB1*0404 haplotypes. In the present study, we aimed to refine these associations further using a combination of genotyping and gene expression studies. METHODS Thirty-nine nucleotide polymorphisms (SNPs) were genotyped in 95 DRB1*0404 carrying unrelated RA cases, 125 DRB1*0404-carrying healthy controls and 87 parent-case trio RA families in which the affected child carried HLA-DRB1*04. Quantitative RT-PCR was used to assess the expression of the positional candidate MHC class III genes APOM, BAT2, BAT3, BAT4, BAT5, AIF1, C6orf47, CSNK2beta and LY6G5C, and the housekeeper genes, hypoxanthine-guanine phosphoribosyltransferase (HPRT) and beta(2)-microglobulin (B2M) in 31 RA cases and 21 ethnically, age- and sex-matched healthy controls. Synovial membrane specimens from RA, PsA and OA cases were stained by an indirect immunoperoxidase technique using a mouse-anti-human AIF1 monoclonal antibody. RESULTS Association was observed between RA and single markers or two marker haplotypes involving AIF1, BAT3 and CSNK. AIF1 was also significantly overexpressed in RA mononuclear cells (1.5- to 1.9-fold difference, P = 0.02 vs HPRT, P = 0.002 vs B2M). AIF1 protein was clearly expressed by synovial macrophages in all the inflammatory synovial samples in contrast to the non-inflammatory OA samples. CONCLUSIONS The results of the genotyping and expression studies presented here suggest a role for AIF1 in both the aetiology and pathogenesis of RA.
Collapse
Affiliation(s)
- S M J Harney
- Diamantina Institute of Cancer, Immunology and Metabolic Medicine, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Queensland 4102, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Fernando MMA, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, Vyse TJ, Rioux JD. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 2008; 4:e1000024. [PMID: 18437207 PMCID: PMC2291482 DOI: 10.1371/journal.pgen.1000024] [Citation(s) in RCA: 387] [Impact Index Per Article: 24.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
The major histocompatibility complex (MHC) is one of the most extensively studied regions in the human genome because of the association of variants at this locus with autoimmune, infectious, and inflammatory diseases. However, identification of causal variants within the MHC for the majority of these diseases has remained difficult due to the great variability and extensive linkage disequilibrium (LD) that exists among alleles throughout this locus, coupled with inadequate study design whereby only a limited subset of about 20 from a total of approximately 250 genes have been studied in small cohorts of predominantly European origin. We have performed a review and pooled analysis of the past 30 years of research on the role of the MHC in six genetically complex disease traits - multiple sclerosis (MS), type 1 diabetes (T1D), systemic lupus erythematosus (SLE), ulcerative colitis (UC), Crohn's disease (CD), and rheumatoid arthritis (RA) - in order to consolidate and evaluate the current literature regarding MHC genetics in these common autoimmune and inflammatory diseases. We corroborate established MHC disease associations and identify predisposing variants that previously have not been appreciated. Furthermore, we find a number of interesting commonalities and differences across diseases that implicate both general and disease-specific pathogenetic mechanisms in autoimmunity.
Collapse
Affiliation(s)
- Michelle M. A. Fernando
- Section of Molecular Genetics and Rheumatology, Faculty of Medicine, Imperial College London, London, United Kingdom
| | - Christine R. Stevens
- Program in Medical and Population Genetics, Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, United States of America
| | - Emily C. Walsh
- Program in Medical and Population Genetics, Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, United States of America
| | - Philip L. De Jager
- Program in Medical and Population Genetics, Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, United States of America
- Department of Neurology, Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
- Harvard Medical School/Partners Healthcare Center for Genetics and Genomics, Boston, Massachusetts, United States of America
| | - Philippe Goyette
- Université de Montréal, Montréal Heart Institute, Montréal, Québec, Canada
| | - Robert M. Plenge
- Program in Medical and Population Genetics, Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, United States of America
- Harvard Medical School, Division of Rheumatology, Allergy and Immunology, Boston, Massachusetts, United States of America
| | - Timothy J. Vyse
- Section of Molecular Genetics and Rheumatology, Faculty of Medicine, Imperial College London, London, United Kingdom
| | - John D. Rioux
- Program in Medical and Population Genetics, Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, United States of America
- Université de Montréal, Montréal Heart Institute, Montréal, Québec, Canada
| |
Collapse
|
9
|
Castiblanco J, Anaya JM. The IkappaBL gene polymorphism influences risk of acquiring systemic lupus erythematosus and Sjögren's syndrome. Hum Immunol 2007; 69:45-51. [PMID: 18295675 DOI: 10.1016/j.humimm.2007.11.008] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2007] [Revised: 11/13/2007] [Accepted: 11/28/2007] [Indexed: 11/19/2022]
Abstract
The human inhibitory kappaB-like gene (IkappaBL) maps to a chromosomal region approximately 25 kb telomeric of the TNF gene at 6p21.3. IkappaBL encodes a protein related to IkappaBalpha that may interact with members of the NF-kappaB/Rel family. We evaluated the role of IkappaBL gene polymorphism in systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS). Genomic DNA isolated from individuals with SLE (n = 134), pSS (n = 67) and from individuals matched for age, sex, and ethnicity (n = 423) was genotyped for Delta-473, -62T/A and +738T/C polymorphisms. The -62A allele was associated with a decrease in the risk of acquiring SLE in a recessive manner; whereas the +738C allele was associated with a more than twofold and threefold increase in the risk of SLE and pSS respectively, relative to the +738T allele. Four haplotypes were observed for the IkappaBL polymorphisms. Haplotype -62A+738T (AT) was associated with a 37% decrease in the risk of SLE, whereas AC tended to increase the risk of developing pSS. Using previously reported TNF data, an almost twofold increased in the risk of SLE was observed between haplotypes IKBL-62T+738T/TNF-308G-238G (TTGG) and TTAG because of linkage disequilibrium between IKBL-62T and TNF-308A. Our findings indicate that the IkappaBL gene influences the risk of developing SLE and pSS.
Collapse
Affiliation(s)
- John Castiblanco
- Cellular Biology and Immunogenetics Unit, Corporación para Investigaciones Biológicas, Medellín, Colombia
| | | |
Collapse
|
10
|
Nemec P, Pavkova-Goldbergova M, Stouracova M, Vasku A, Soucek M, Gatterova J. Polymorphism in the tumor necrosis factor-alpha gene promoter is associated with severity of rheumatoid arthritis in the Czech population. Clin Rheumatol 2007; 27:59-65. [PMID: 17562093 DOI: 10.1007/s10067-007-0653-7] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2006] [Revised: 04/02/2007] [Accepted: 05/15/2007] [Indexed: 10/23/2022]
Abstract
Rheumatoid arthritis (RA) is a model of multigenic inflammatory disorder in which tumor necrosis factor-alpha (TNF-alpha) plays an important role. Genetic factors may be implicated in the susceptibility to disease initiation as well as in severity of disease course. Elevated levels of TNF-alpha in the plasma and synovial fluid from RA patients may be associated with polymorphisms in the promoter region of the TNF-alpha gene. The aim of this study was to elucidate putative association between the -308 G/A polymorphism in the promoter region of the TNF-alpha gene and susceptibility to onset and severity of RA. A total of 130 RA patients and a control group of 150 healthy subjects with similar age and sex distribution were available for the study. All patients fulfilled the American College of Rheumatology revised criteria for RA. RA patients had a disease duration of at least 2 years. Radiographs of both hands of all RA patients were scored with the Steinbrocker method. There were 15 patients of stage I (nonerosive form) of RA and 114 patients of stages II-IV (erosive form). To assess the RA patient's functional ability, the Health Assessment Questionnaire (HAQ) was used. The -308 G/A promoter polymorphism of the TNF-alpha gene was detected by polymerase chain reaction and restriction fragment length polymorphism analysis. No differences in genotype distribution and allelic frequences of -308 G/A TNF-alpha promoter polymorphism have been found between RA patients and the control group. Significant differences have been observed within the RA group divided according to the radiographic progression of disease based on the Steinbrocker radiographic score and functional ability (HAQ). These results suggest an association of the -308 G/A polymorphism of the TNF-alpha gene with the severity of RA.
Collapse
Affiliation(s)
- Petr Nemec
- Rheumatology Division, 2nd Department of Internal Medicine, St. Anne's University Hospital, Pekarská 53, 656 91, Brno, Czech Republic.
| | | | | | | | | | | |
Collapse
|
11
|
Mallya M, Campbell RD, Aguado B. Characterization of the five novel Ly-6 superfamily members encoded in the MHC, and detection of cells expressing their potential ligands. Protein Sci 2007; 15:2244-56. [PMID: 17008713 PMCID: PMC2242401 DOI: 10.1110/ps.062242606] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Lymphocyte Antigen 6 (Ly-6) superfamily members are cysteine-rich, generally GPI-anchored cell surface proteins, which have definite or putative immune related roles. There are 27 members of this family described so far in the human genome and 37 in the mouse. Five of them are clustered in the class III region of the human and mouse MHCs. Following computational analyses, we functionally characterized the encoded proteins by creating epitope-tagged fusion constructs to determine molecular weight, complex formation, subcellular localization, post-translational modifications and ligand binding. We found that all human and mouse proteins were glycosylated, and most could form part of larger complexes. Human and mouse Ly6G6c and Ly6G6d, and mouse Ly6g6e were found to be GPI-anchored cell surface proteins, highly expressed at the leading edges of cells, on filopodia, which are normally involved in cell adhesion and migration. However, analysis of Ly6G5c and Ly6G5b indicated that they are potentially secreted proteins. Our results indicate that there are two subclusters of related Ly-6 proteins in this region of the MHC, with Ly6G6c, Ly6G6d, and Ly6G6e forming one and Ly6G5c and Ly6G5b forming another. In addition, by FACS analysis we have found that the potential ligands for human LY6G6C, LY6G6D, and LY6G5C are expressed on K562 cells, an undifferentiated megakaryocyte cell line, indicating a potential role in hematopoietic cell differentiation. This characterization of the five MHC class III region Ly-6 family members is of great relevance, as they represent 18% of the human Ly-6 protein family and 50% of the secreted ones.
Collapse
Affiliation(s)
- Meera Mallya
- MRC Rosalind Franklin Centre for Genomics Research, Hinxton, Cambridge CB10 1SB, United Kingdom
| | | | | |
Collapse
|
12
|
Steer S, Abkevich V, Gutin A, Cordell HJ, Gendall KL, Merriman ME, Rodger RA, Rowley KA, Chapman P, Gow P, Harrison AA, Highton J, Jones PBB, O'Donnell J, Stamp L, Fitzgerald L, Iliev D, Kouzmine A, Tran T, Skolnick MH, Timms KM, Lanchbury JS, Merriman TR. Genomic DNA pooling for whole-genome association scans in complex disease: empirical demonstration of efficacy in rheumatoid arthritis. Genes Immun 2006; 8:57-68. [PMID: 17159887 DOI: 10.1038/sj.gene.6364359] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
A pragmatic approach that balances the benefit of a whole-genome association (WGA) experiment against the cost of individual genotyping is to use pooled genomic DNA samples. We aimed to determine the feasibility of this approach in a WGA scan in rheumatoid arthritis (RA) using the validated human leucocyte antigen (HLA) and PTPN22 associations as test loci. A total of 203 269 single-nucleotide polymorphisms (SNPs) on the Affymetrix 100K GeneChip and Illumina Infinium microarrays were examined. A new approach to the estimation of allele frequencies from Affymetrix hybridization intensities was developed involving weighting for quality signals from the probe quartets. SNPs were ranked by z-scores, combined from United Kingdom and New Zealand case-control cohorts. Within a 1.7 Mb HLA region, 33 of the 257 SNPs and at PTPN22, 21 of the 45 SNPs, were ranked within the top 100 associated SNPs genome wide. Within PTPN22, individual genotyping of SNP rs1343125 within MAGI3 confirmed association and provided some evidence for association independent of the PTPN22 620W variant (P=0.03). Our results emphasize the feasibility of using genomic DNA pooling for the detection of association with complex disease susceptibility alleles. The results also underscore the importance of the HLA and PTPN22 loci in RA aetiology.
Collapse
Affiliation(s)
- S Steer
- Kings College London School of Medicine at Guy's, Department of Rheumatology, King's and St Thomas', London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Mewar D, Marinou I, Lee ME, Timms JM, Kilding R, Teare MD, Read RC, Wilson AG. Haplotype-specific gene expression profiles in a telomeric major histocompatibility complex gene cluster and susceptibility to autoimmune diseases. Genes Immun 2006; 7:625-31. [PMID: 16971954 DOI: 10.1038/sj.gene.6364339] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The telomeric class III region of the major histocompatibility complex is gene dense, but apart from the three tumour necrosis factor (TNF) superfamily members (TNF, lymphotoxin alpha and lymphotoxin beta) little is known of the expression and function of the majority of the genes. Recent genetic studies in autoimmune diseases, particularly rheumatoid arthritis (RA), have suggested a human leukocyte antigen (HLA)-DR-independent disease effect in this region. To gain further insights into these associations, we used lipopolysaccharide-stimulated human macrophages to examine inducible mRNA expression and genotype-phenotype relationships for genes in this region. Following stimulation in addition to the expected induction of TNF mRNA, a 14-fold increase of ATP6V1G2 at 18 h (P<0.001) was seen, whereas B-associated transcript (BAT)2 (P<0.001) and leucocyte-specific transcript (LST)1 (P<0.001) were both downregulated. By genotyping single-nucleotide polymorphisms spanning a 70 kb interval centred on the TNF locus, we constructed haplotypes and determined associated expression profiles for 10 genes in the cluster using quantitative real-time polymerase chain reaction. Overexpression of BAT1 mRNA was associated with carriers of a haplotype containing the LST1 marker transmitted to RA cases in a family study and also DRB1(*)15 associated with susceptibility to nephritis in systemic lupus erythematosus. The implications of our findings for the understanding of genetic associations with disease susceptibility in this region are discussed.
Collapse
Affiliation(s)
- D Mewar
- School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Dieudé P, Cornélis F. Genetic basis of rheumatoid arthritis. Joint Bone Spine 2005; 72:520-6. [PMID: 16309943 DOI: 10.1016/j.jbspin.2005.09.001] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2004] [Accepted: 09/14/2005] [Indexed: 01/01/2023]
Abstract
Rheumatoid arthritis (RA) is a multifactorial disease due to a combination of genetic and environmental factors. Identification of the genetic factors involved in the pathogenesis of RA should open up avenues for developing radical treatment strategies directed at the cause of the disease. The Association de Recherche sur la Polyarthrite (ARP) supports research in this field, in which our group has been involved since 1993. Thanks to this support, considerable progress has been made. Several combinations of susceptibility alleles of various genes are probably involved in the development of RA. Although HLA-DRB1 is the main RA gene, it accounts for only part of the familial risk for RA. HLA-DRB1 alleles are neither necessary nor sufficient to cause the development of RA in a given individual. Several genome scans conducted in populations from France, Japan, North America and UK have confirmed the role of the HLA region and suggested several other susceptibility loci. Association studies support a role for several genes, including TNFR2, PADI4, SLC22A4, RUNX1, and PTPN22. However, the imperfect matching of cases and controls requires that confirmation of these results be obtained. To confirm that a gene confers susceptibility to RA, the association must be replicated in several independent studies and, more importantly, evidence of genetic linkage must be obtained in family studies. The identification of genetic factors conferring susceptibility to RA will open up new avenues toward radical treatments for RA and may help to optimize the diagnostic, prognostic, and pharmacogenetic management of today's patients with RA.
Collapse
Affiliation(s)
- Philippe Dieudé
- GenHotel - EA3886, European Research Laboratory for Rheumatoid Arthritis, Evry-Paris 7 University, 2, rue Gaston Crémieux, 91000 Evry, and Rheumatology Federation, Lariboisière Teaching Hospital, 75010 Paris, France
| | | |
Collapse
|
15
|
Verpoort KN, van Gaalen FA, van der Helm-van Mil AHM, Schreuder GMT, Breedveld FC, Huizinga TWJ, de Vries RRP, Toes REM. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. ACTA ACUST UNITED AC 2005; 52:3058-62. [PMID: 16200610 DOI: 10.1002/art.21302] [Citation(s) in RCA: 124] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Recent data have shown that the most prominent and longest known genetic risk factors for rheumatoid arthritis (RA), HLA-DRB1 shared epitope alleles, are only associated with RA that is characterized by the presence of antibodies against cyclic citrullinated peptide (anti-CCP antibodies) and not with anti-CCP-negative RA. We undertook this study to investigate whether anti-CCP-negative RA is associated with other HLA-DRB1 alleles. METHODS HLA typing was performed for 377 patients from the Leiden Early Arthritis Clinic who were diagnosed as having RA within the first year of followup (206 anti-CCP-positive patients and 171 anti-CCP-negative patients), 235 patients who, after 1 year, had undifferentiated arthritis (UA) (28 anti-CCP-positive patients and 207 anti-CCP-negative patients), and 423 healthy control subjects. Odds ratios (ORs) with 95% confidence intervals (95% CIs) for HLA-DRB1 allele frequencies were determined for all patient groups compared with the healthy control group. RESULTS HLA-DR3 was more frequently present in the anti-CCP-negative RA group than in the control group (OR 1.84, 95% CI 1.26-2.67). This was not the case for anti-CCP-positive RA (OR 0.92, 95% CI 0.60-1.40). HLA-DR3 was also more frequently present in anti-CCP-negative UA patients (OR 1.59, 95% CI 1.10-2.28), but not in anti-CCP-positive UA patients (OR 0.68, 95% CI 0.17-1.92). CONCLUSION HLA-DR3 is associated with anti-CCP-negative arthritis and not with anti-CCP-positive arthritis. These data show that distinct genetic risk factors are associated with the presence of anti-CCP antibodies in RA and indicate that different pathogenetic mechanisms underlie anti-CCP-positive and anti-CCP-negative RA.
Collapse
Affiliation(s)
- Kirsten N Verpoort
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
de Vries RRP, Huizinga TWJ, Toes REM. Redefining the HLA and RA association: to be or not to be anti-CCP positive. J Autoimmun 2005; 25 Suppl:21-5. [PMID: 16257178 DOI: 10.1016/j.jaut.2005.09.005] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2005] [Revised: 08/02/2005] [Accepted: 09/06/2005] [Indexed: 10/25/2022]
Abstract
Rheumatoid Arthritis (RA) is the most common chronic inflammatory joint disease. The overall prevalence is 1% and in people older than 60 it is more than 2%. RA has auto-immune features: auto-antibodies against the Fc part of IgG, so-called Rheumatoid Factor (RF) are found more often in RA patients and more recently RA-specific auto-antibodies directed against Cyclic Citrunilated Peptides (CCP) have been discovered. Based on twin studies the contribution of genetic factors to the pathogenesis has been estimated to be about 60%. The main genetic contribution (about 40%) comes from the HLA complex. An association between HLA-DR4 and RA was already documented almost 30 years ago. This association was more prominent for severe forms of the disease. Because more HLA-DRB1 alleles appeared to be associated with RA and the products of these alleles shared a 5AA sequence in a peptide-binding pocket the so-called Shared Epitope (SE) hypothesis was formulated, the prediction being that these DRB1 molecules would bind an RA inducing peptide(s). Thus far however such (a) peptides remain elusive. Because the risk for RA associated with different but SE-identical DRB1 alleles varies considerably this SE can also not be the whole explanation for the HLA contribution to RA susceptibility/severity. A modified SE has been postulated and a role for DQ has been postulated. There is also evidence for a contribution of non-class II genes to susceptibility. About 5 years ago we have reported that certain HLA-DRB1 alleles are associated with protection from (severe) RA. The products of these alleles carry instead of the SE sequence another peptide anchor region consisting of the amino acid DERAA. In a large prospective cohort study we showed recently that these alleles indeed confer (dominant) protection both against developing RA and a severe course of the disease. This protection was observed both in the presence and the absence of SE susceptibility alleles. We are presently exploring the hypothesis that this protection is mediated by regulatory T cells reactive with the DERAA epitope. An obvious way to unravel the apparently complex association between HLA and RA is to reduce the heterogeneity of this multifactorial disease. Recently, we have discovered that SE positive DRB1 alleles are exclusively associated with CCP positive RA. The previously reported association with RF positive RA appeared to be secondary to the association with anti-CCP pos. RA. This was the case both for the association found for susceptibility and severity. Interestingly, DRB1*03 was exclusively associated with anti-CCP neg. RA. Because recent evidence puts the immune response against citrunilated proteins (CCP) as prime suspect for disease induction and progression in this subgroup of RA these observations are a big leap forwards in solving the HLA-RA puzzle.
Collapse
Affiliation(s)
- René R P de Vries
- Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Building 1, E3-Q, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
| | | | | |
Collapse
|
17
|
Kilding R, Wilson AG. Mapping of a novel susceptibility gene for rheumatoid arthritis in the telomeric MHC region. Cytokine 2005; 32:71-5. [PMID: 16199168 DOI: 10.1016/j.cyto.2005.07.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Rheumatoid arthritis (RA) is a complex heterogeneous disease with an estimated genetic contribution to of 30-50%. Approximately one third arises from the major histocompatibility complex (MHC) at 6p21.3. The contribution of specific DRB1 alleles encoding the shared epitope has been well described, however, several recent studies have suggested that additional telomeric genetic influences may exist. This region is difficult to study as a result of the presence of strong linkage disequilibrium (LD) within the MHC and high gene density particularly in the central class III region. In this article we review the current data supporting the existence of a non-DRB1 susceptibility gene for rheumatoid arthritis, in particular within the class III region.
Collapse
Affiliation(s)
- Rachael Kilding
- Division of Genomic Medicine, The University of Sheffield, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, United Kingdom
| | | |
Collapse
|
18
|
Addo A, Le J, Li W, Aksentijevich I, Balow J, Lee A, Gregersen PK, Kastner DL, Remmers EF. Analysis of CARD15/NOD2 haplotypes fails to identify common variants associated with rheumatoid arthritis susceptibility. Scand J Rheumatol 2005; 34:198-203. [PMID: 16134725 DOI: 10.1080/03009740510018561] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
OBJECTIVES The CARD15/NOD2 gene product plays an important role in host response to bacterial lipopolysaccharides and bacterial muramyl dipeptide via activation of NF-kappaB in monocytes. Mutations in CARD15 are associated with Crohn's disease (CD), a chronic inflammatory bowel disease. In this study we sought to determine whether CD-associated mutations or any common variants of this gene might contribute to susceptibility to another chronic inflammatory disease, rheumatoid arthritis (RA). METHODS We genotyped 376 Caucasian RA cases and 376 ethnically matched healthy controls for three CD-associated CARD15 mutations. We also genotyped these 752 individuals for 12 common CARD15 single nucleotide polymorphisms (SNPs), determined the linkage disequilibrium structure of the gene, and compared the frequencies of the common CARD15 haplotypes in the RA cases and controls. RESULTS None of the CD-associated mutations or the CARD15 SNPs was associated with susceptibility to RA. We also found no significant difference in the frequencies of any of the common haplotypes of the CARD15 gene in RA patients and controls. Our haplotype analysis was consistent with earlier observations that all three CD-associated variants independently arose on the same ancestral haplotype. CONCLUSIONS These data suggest that CARD15 variants are not associated with RA susceptibility.
Collapse
Affiliation(s)
- A Addo
- Genetics and Genomics Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD 20892-0908, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Affiliation(s)
- Jorge R Oksenberg
- Department of Neurology, University of California at San Francisco, School of Medicine, 513 Parnassus Avenue S-256, San Francisco, CA 94143-0435, USA.
| | | |
Collapse
|
20
|
Price P, Santoso L, Mastaglia F, Garlepp M, Kok CC, Allcock R, Laing N. Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3. ACTA ACUST UNITED AC 2005; 64:575-80. [PMID: 15496200 DOI: 10.1111/j.1399-0039.2004.00310.x] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Previous studies of sporadic inclusion body myositis (sIBM) have shown a strong association with HLA-DR3 and other components of the 8.1 ancestral haplotype (AH) (HLA-A1, B8, DR3), where the susceptibility locus has been mapped to the central major histocompatibility complex (MHC) region between HLA-DR and C4. Here, the association with HLA-DR3 and other genes in the central MHC and class II region was further investigated in a group of 42 sIBM patients and in an ethnically similar control group (n = 214), using single-nucleotide polymorphisms and microsatellite screening. HLA-DR3 (marking DRB1*0301 in Caucasians) was associated with sIBM (Fisher's test). However, among HLA-DR3-positive patients and controls, carriage of HLA-DR3 without microsatellite and single-nucleotide polymorphism alleles of the 8.1AH (HLA-A1, B8, DRB3*0101, DRB1*0301, DQB1*0201) was marginally less common in patients. Patients showed no increase in carriage of the 18.2AH (HLA-A30, B18, DRB3*0202, DRB1*0301, DQB1*0201) or HLA-DR3 without the central MHC of the 8.1AH, further arguing against HLA-DRB1 as the direct cause of susceptibility. Genes between HLA-DRB1 and HOX12 require further investigation. BTL-II lies in this region and is expressed in muscle. Carriage of allele 2 (exon 6) was more common in patients. BTL-II(E6)*2 is characteristic of the 35.2AH (HLA-A3, B35, DRB1*01) in Caucasians and HLA-DR1, BTL-II(E6)*2, HOX12*2, RAGE*2 was carried by several patients. The 8.1AH and 35.2AH may confer susceptibility to sIBM independently or share a critical allele.
Collapse
Affiliation(s)
- P Price
- School of Surgery and Pathology, University of Western Australia, Nedlands, Australia.
| | | | | | | | | | | | | |
Collapse
|
21
|
Wirtz PW, Willcox N, van der Slik AR, Lang B, Maddison P, Koeleman BPC, Giphart MJ, Wintzen AR, Roep BO, Verschuuren JJGM. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert–Eaton myasthenic syndrome. J Neuroimmunol 2005; 159:230-7. [PMID: 15652424 DOI: 10.1016/j.jneuroim.2004.10.018] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2004] [Accepted: 10/19/2004] [Indexed: 11/29/2022]
Abstract
Patients with small cell lung cancer (SCLC) survive longer if they have the antibody-mediated Lambert-Eaton myasthenic syndrome (LEMS), making this autoimmune disorder a prototype disease for studying cancer immunosurveillance. Patients with nontumor LEMS (NT-LEMS) never develop SCLC but are otherwise indistinguishable clinically. Therefore, we have compared immunogenetic factors in SCLC-LEMS and NT-LEMS and studied their role in the pathogenesis of LEMS and survival from SCLC. In 48 British and 29 Dutch Caucasian LEMS patients, we studied clinical symptoms, antibody titers, HLA types and alleles at six nearby located microsatellite loci. Highly significant associations were found in NT-LEMS, which appeared strongest with HLA-B8, but also involved HLA-DQ2, -DR3 and six flanking microsatellite alleles. SCLC-LEMS patients were not different from controls. Smoking was a strong predictor of SCLC. In contrast, HLA-B8 positivity correlated with a decreased risk of SCLC even among the smokers. Moreover, in SCLC-LEMS patients, HLA-B8 positivity correlated with prolonged survival after LEMS onset. We propose that two distinct immunopathogenetic routes can lead to one clinically and serologically indistinguishable autoimmune myasthenic syndrome. HLA-DR3-B8 is strongly associated with LEMS in nontumor patients only. In other LEMS patients, SCLC apparently provides a powerful autoimmunogenic stimulus that overrides HLA restrictions in breaking tolerance to calcium channels. Moreover, negativity for HLA-B8 combined with smoking behavior points more strongly to an underlying SCLC and predicts a worse prognosis in SCLC-LEMS patients.
Collapse
Affiliation(s)
- Paul W Wirtz
- Department of Neurology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Vandiedonck C, Giraud M, Garchon HJ. Genetics of autoimmune myasthenia gravis: The multifaceted contribution of the HLA complex. J Autoimmun 2005; 25 Suppl:6-11. [PMID: 16260117 DOI: 10.1016/j.jaut.2005.09.010] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2005] [Revised: 06/20/2005] [Accepted: 09/07/2005] [Indexed: 11/27/2022]
Abstract
The HLA complex plays a prominent role in predisposition to many autoimmune diseases. Thus far, the highly polymorphic class I and class II loci have been considered as the prime candidates to explain this role. There is nonetheless growing evidence that other closely linked HLA loci are also involved in autoimmune susceptibility. Their search, however, has been hampered by the often strong linkage disequilibria, i.e. the non-random association of alleles at linked loci, across the HLA complex. Here, we discuss recent work from our laboratory on the dissection of this emblematic genetic region in a model autoimmune disease, acquired myasthenia gravis (MG).
Collapse
Affiliation(s)
- Claire Vandiedonck
- Inserm U580, Université Paris Descartes, 161 rue de Sèvres, 75743 Paris Cedex 15, France
| | | | | |
Collapse
|
23
|
Vandiedonck C, Beaurain G, Giraud M, Hue-Beauvais C, Eymard B, Tranchant C, Gajdos P, Dausset J, Garchon HJ. Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia. Proc Natl Acad Sci U S A 2004; 101:15464-9. [PMID: 15489265 PMCID: PMC524438 DOI: 10.1073/pnas.0406756101] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The 8.1 haplotype of the HLA complex has been reproducibly associated with several autoimmune diseases and traits, notably with thymus hyperplasia in patients with acquired generalized myasthenia gravis, an autoantibody-mediated disease directed at the muscle acetylcholine receptor. However, the strong linkage disequilibrium across this haplotype has prevented the identification of the causative locus, termed MYAS1. Here, we localized MYAS1 to a 1.2-Mb genome segment by reconstructing haplotypes and assessing their transmission in 73 simplex families. This segment encompasses the class III and proximal class I regions, between the BAT3 and C3-2-11 markers, therefore unambiguously excluding the class II loci. In addition, a case-control study revealed a very strong association with a core haplotype in this same region following an additive model (P=7 x 10(-11), odds ratio 6.5 for one copy and 42 for two copies of the core haplotype). Finally, we showed that this region is associated with a marked increase in serum titers of anti-acetylcholine receptor autoantibodies (P=8 x 10(-6)). Remarkably, this effect was suppressed by a second locus in cis on the 8.1 haplotype and located toward the class II region. Altogether, these data demonstrate the highly significant but complex effects of the 8.1 haplotype on the phenotype of myasthenia gravis patients and might shed light on its role in other autoimmune diseases.
Collapse
Affiliation(s)
- Claire Vandiedonck
- Institut National de la Santé et de la Recherche Médicale U580 and Institut de Recherche Necker Enfants Malades, 161 Rue de Sèvres, 75743 Paris Cedex 15, France
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Collado L, Rueda B, Cáliz R, Torres B, García A, Nuñez-Roldan A, González-Escribano MF, Martin J. Lack of association between the IκBL promoter polymorphism and rheumatoid arthritis. ACTA ACUST UNITED AC 2004; 50:2032-3. [PMID: 15188381 DOI: 10.1002/art.20215] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
25
|
Newton JL, Harney SMJ, Wordsworth BP, Brown MA. A review of the MHC genetics of rheumatoid arthritis. Genes Immun 2004; 5:151-7. [PMID: 14749714 DOI: 10.1038/sj.gene.6364045] [Citation(s) in RCA: 185] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Rheumatoid arthritis is a common complex genetic disease, and, despite a significant genetic element, no gene other than HLA-DRB1 has been clearly demonstrated to be involved in the disease. However, this association accounts for less than half the overall genetic susceptibility. Investigation of other candidate genes, in particular those that reside within the major histocompatibility complex, are hampered by the presence of strong linkage disequilibrium and problems with study design.
Collapse
Affiliation(s)
- J L Newton
- Institute of Musculoskeletal Sciences, University of Oxford, The Botnar Research Centre, Nuffield Orthopaedic Centre, Headington, Oxford, UK
| | | | | | | |
Collapse
|
26
|
Barton A, Platt H, Salway F, Symmons D, Barrett E, Bukhari M, Lunt M, Zeggini E, Eyre S, Hinks A, Tellam D, Brintnell B, Ollier W, Worthington J, Silman A. Polymorphisms in the tumour necrosis factor gene are not associated with severity of inflammatory polyarthritis. Ann Rheum Dis 2004; 63:280-4. [PMID: 14962963 PMCID: PMC1754913 DOI: 10.1136/ard.2003.008680] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Tumour necrosis factor alpha (TNFalpha) is a powerful inflammatory mediator in rheumatoid and other types of inflammatory arthritis. Polymorphisms within the TNFalpha gene have previously been investigated to determine their role in the aetiopathogenesis of rheumatoid arthritis (RA), but it is unclear whether reported associations are with susceptibility to, or severity of, disease. OBJECTIVE To examine the association between both individual TNFalpha single nucleotide polymorphisms (SNPs) and haplotypes with the development and severity of erosions by 5 years in patients with inflammatory polyarthritis (IP). METHODS 438 patients from the Norfolk Arthritis Register observational inception cohort of patients with IP were x rayed 5 years after disease onset. They were genotyped for nine SNPs mapping to the TNFalpha gene, using a SNaPshot primer extension assay. Haplotypes were constructed in patients with IP, who were compared for the presence and extent of erosions at 5 years. RESULTS No association between individual TNFalpha SNPs or haplotypes in the patients who developed erosions at 5 years compared with those who remained non-erosive was found. Restricting analysis to patients who satisfied ACR criteria for RA by 5 years did not affect the conclusions. CONCLUSION The TNFalpha gene does not seem to be associated with severity as assessed by erosive outcome at 5 years in patients with IP.
Collapse
|
27
|
Kilding R, Iles MM, Timms JM, Worthington J, Wilson AG. Additional genetic susceptibility for rheumatoid arthritis telomeric of the DRB1 locus. ACTA ACUST UNITED AC 2004; 50:763-9. [PMID: 15022317 DOI: 10.1002/art.20043] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
OBJECTIVE Rheumatoid arthritis (RA) has an estimated genetic contribution of 30-50%, approximately one-third of which arises from the major histocompatibility complex on 6p21.3. Many studies have implicated alleles of DRB1 that encode a shared epitope. However, several recent studies have suggested that additional telomeric genetic influences may exist. In this study, we sought to investigate whether a separate non-DRB1 effect could be detected and to determine its likely location. METHODS We typed 13 single-nucleotide polymorphisms, located mainly in the telomeric class III region of the major histocompatibility complex, in 164 British Caucasian families with RA that had at least 1 affected offspring and used unconditioned and DRB1-conditioned transmission disequilibrium tests (TDTs). RESULTS Unconditioned TDTs revealed overtransmission of shared epitope alleles (P = 2.12 x 10(-5)) and an allele of the HLA-B-associated transcript 1 (BAT1) gene in the telomeric class III region (P = 0.009). Using a DRB1-conditioned TDT to assess whether an independent effect existed, we detected unequal transmission of alleles of lymphocyte-specific transcript 1 (P = 0.004), BAT1 (P = 0.003), and PG8 (P = 0.003). CONCLUSION At least 1 additional non-DRB1 susceptibility locus for RA exists in an interval that encompasses the junction of the class III and I regions. This is a genomic segment of high linkage disequilibrium containing a large number of poorly characterized immunomodulatory genes.
Collapse
Affiliation(s)
- Rachael Kilding
- The University of Sheffield, Royal Hallamshire Hospital, Sheffield, UK
| | | | | | | | | |
Collapse
|
28
|
Barton A, John S. Approaches to identifying genetic predictors of clinical outcome in rheumatoid arthritis. AMERICAN JOURNAL OF PHARMACOGENOMICS : GENOMICS-RELATED RESEARCH IN DRUG DEVELOPMENT AND CLINICAL PRACTICE 2004; 3:181-91. [PMID: 12814326 DOI: 10.2165/00129785-200303030-00004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Predicting which patients with rheumatoid arthritis (RA), at presentation, are likely to suffer a severe disease course based on genotype data would be a major clinical advance. It would ensure that patients at highest risk of a severe outcome could be targeted with early aggressive therapies. With a better understanding of interactions between genotype and drug response it would be possible to prescribe treatments most likely to be efficacious and safe for specific patient subgroups. While a clear genetic component has been demonstrated in RA severity, the identification of genetic factors poses a challenge to researchers in the field. Initiatives such as the SNP Consortium and advances in genotyping technology have facilitated the investigation of genetic factors in both disease susceptibility and severity. However, several other factors, such as the availability of suitable longitudinal cohorts, definition of outcome measures, study design, selection of genetic markers, and statistical power, will all contribute to the likely success of genetic studies. Several strategies that have been applied in the pursuit of genetic predictors of clinical outcome in RA. While some encouraging results have been generated, it has so far been difficult to quantify the predictive value of genetic markers and extrapolate the results from genetic studies to clinic patients. Establishing high quality prospective inception cohorts, a more systemic approach to defining suitable outcome measures, and understanding the effects of treatment, will be critical to the eventual identification of good predictive genetic markers.
Collapse
Affiliation(s)
- Anne Barton
- School of Epidemiology and Health Sciences, University of Manchester, Manchester, England, UK
| | | |
Collapse
|
29
|
Lehner B, Semple JI, Brown SE, Counsell D, Campbell RD, Sanderson CM. Analysis of a high-throughput yeast two-hybrid system and its use to predict the function of intracellular proteins encoded within the human MHC class III region. Genomics 2004; 83:153-67. [PMID: 14667819 DOI: 10.1016/s0888-7543(03)00235-0] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
High-throughput (HTP) protein-interaction assays, such as the yeast two-hybrid (Y2H) system, are enormously useful in predicting the functions of novel gene-products. HTP-Y2H screens typically do not include all of the reconfirmation and specificity tests used in small-scale studies, but the effects of omitting these steps have not been assessed. We performed HTP-Y2H screens that included all standard controls, using the predicted intracellular proteins expressed from the human MHC class III region, a region of the genome associated with many autoimmune diseases. The 91 novel interactions identified provide insight into the potential functions of many MHC genes, including C6orf47, LSM2, NELF-E (RDBP), DOM3Z, STK19, PBX2, RNF5, UAP56 (BAT1), ATP6G2, LST1/f, BAT2, Scythe (BAT3), CSNK2B, BAT5, and CLIC1. Surprisingly, our results predict that 1/3 of the proteins may have a role in mRNA processing, which suggests clustering of functionally related genes within the human genome. Most importantly, our analysis shows that omitting standard controls in HTP-Y2H screens could significantly compromise data quality.
Collapse
Affiliation(s)
- Ben Lehner
- Functional Genomics Group, MRC Rosalind Franklin Centre for Genomics Research, Hinxton, Cambridge, United Kingdom
| | | | | | | | | | | |
Collapse
|
30
|
Abstract
This chapter reviews the latest original research on the genetics of rheumatoid arthritis (RA), with a focus on its relevance for the clinical rheumatologist. The following questions will be dealt with in order to appreciate the recent progress in this field. * Why is a knowledge of genetics useful for an understanding of the pathogenesis of RA? * Is a knowledge of genetic risk factors relevant for day-to-day clinical practice? * What methods are used for identifying genetic risk factors? * Which genetic regions have been identified in susceptibility to RA? * What risk factors have been identified? * What are the future prospects and research agenda?
Collapse
Affiliation(s)
- Tom W J Huizinga
- Department of Rheumatology, C4-R, Leiden University Medical Center, P.O. Box 9600, RC 2300, Leiden, The Netherlands.
| |
Collapse
|
31
|
Yu HX, Ren EC, Chan SH. Associations of HLA microsatellites with rheumatoid arthritis in Singaporean Chinese. TISSUE ANTIGENS 2003; 62:133-8. [PMID: 12889993 DOI: 10.1034/j.1399-0039.2003.00084.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Rheumatoid arthritis in Singaporean Chinese has previously been shown to be associated with the DRB1*0405, DRB1*1001 haplotypes and to the DRB1*0901 haplotype when the former two were removed. The present paper focused on eight HLA associated microsatellite markers (TNFa, TNFd, D6S273, TAP1CA, DQCAR, DQCARII, D6S2222, D6S2223) and their allelic associations with Chinese RA. 60 RA patients and 75 healthy controls were studied. It appeared that DQCARII*194/DRB1*0405/TNFa*117 was part of the extended haplotype predisposed to RA, whereas DRB1*0901/D6S273*128 contributed to susceptibility to RA to a lesser degree in Singaporean Chinese. Additionally, a negative association with DQCAR*186/DRB1*0301/D6S273*122/TNFd*124 was observed. No association with disease development was observed in this study.
Collapse
Affiliation(s)
- H X Yu
- WHO Immunology Centre, Faculty of Medicine, National University of Singapore, Republic of Singapore
| | | | | |
Collapse
|
32
|
van de Beek WJT, Roep BO, van der Slik AR, Giphart MJ, van Hilten BJ. Susceptibility loci for complex regional pain syndrome. Pain 2003; 103:93-7. [PMID: 12749963 DOI: 10.1016/s0304-3959(02)00444-x] [Citation(s) in RCA: 82] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
An association between HLA-DR13 and patients with complex regional pain syndrome (CRPS) who progressed towards multifocal or generalized tonic dystonia was recently reported. We now report on a new locus, centromeric in HLA-class I, which was significantly associated with a spontaneous development of CRPS, suggesting an interaction between trauma severity and genetic factors conferring CRPS susceptibility. Additionally, an association with the D6S1014 locus was found, supporting the previous finding of an association with HLA-DR13.
Collapse
Affiliation(s)
- Willem-Johan T van de Beek
- Department of Neurology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands
| | | | | | | | | |
Collapse
|
33
|
Bolognesi E, Karell K, Percopo S, Coto I, Greco L, Mantovani V, Suoraniemi E, Partanen J, Mustalahti K, Mäki M, Momigliano-Richiardi P. Additional factor in some HLA DR3/DQ2 haplotypes confers a fourfold increased genetic risk of celiac disease. TISSUE ANTIGENS 2003; 61:308-16. [PMID: 12753669 DOI: 10.1034/j.1399-0039.2003.00028.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Although HLA-DQ genes are the major celiac disease (CD) susceptibility genes, results from Finnish families suggest that not all DQ2-encoding haplotypes confer equal susceptibility to CD, implying the effect of other gene(s) in the HLA region. The aim of the present work was to extend and confirm the aforementioned results in a southern European population ( Italian) and to better localize the additional risk factor/s. The association of nine loci spanning the HLA region from DR to HFE, 4.5-Mb telomeric of HLA-A, was tested. The analysis was performed by comparing marker frequencies in DR3-DQ2 haplotypes transmitted and non-transmitted to the affected offspring in 156 Italian CD families selected for having at least one DR3-positive parent. The same analysis was performed independently in 101 Finnish CD families selected with the same criteria. Three alleles, MICA-A5.1, MICB-CA24 and MIB-350, all characteristic of the B8-DR3 extended haplotype, showed a significantly increased frequency in DR3 transmitted haplotypes in the Italian families. DR3 haplotypes carrying the combination of these alleles conferred an approximate fourfold increased CD risk. B8-DR3 transmitted haplotypes were significantly more conserved telomerically down to the MIC-Class I region. Similar results were seen in the Finnish families. The major conclusion that holds true in both populations is that, while DQ2 is an absolute requirement for the development of CD, the presence of an additional genetic factor within the MIC-Class I region confers an approximate 4-fold increased risk of the disease.
Collapse
Affiliation(s)
- E Bolognesi
- Department of Medical Sciences, Eastern Piedmont University and I.R.C.A.D. (Interdisciplinary Research Center on Autoimmune Diseases), Novara, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
Genetic factors are increasingly recognized to have an important contribution to the occurrence of both inflammatory and noninflammatory rheumatic disease. Although identifying the specific genetic mechanisms involved in the rheumatic diseases continues to present considerable challenges, the prospect of identifying individual gene action has been brought closer by a number of recent developments. These include newer approaches to phenotype definition, refinements in statistical tools for analysis, and the advent of newer technologies, including the use of microarrays. In this article, we review some of these developments together with the recent literature on the contribution of both broad and specific genetic factors to the spectrum of rheumatic disease. We also consider contemporary opinions on the potential impact of genetic discoveries to human health.
Collapse
Affiliation(s)
- Sophia Steer
- Twin Research and Genetic Epidemiology Unit, St. Thomas' Hospital, London, UK
| | | |
Collapse
|
35
|
Okamoto K, Makino S, Yoshikawa Y, Takaki A, Nagatsuka Y, Ota M, Tamiya G, Kimura A, Bahram S, Inoko H. Identification of I kappa BL as the second major histocompatibility complex-linked susceptibility locus for rheumatoid arthritis. Am J Hum Genet 2003; 72:303-12. [PMID: 12509789 PMCID: PMC379224 DOI: 10.1086/346067] [Citation(s) in RCA: 109] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2002] [Accepted: 10/29/2002] [Indexed: 02/05/2023] Open
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease with a complex etiology in which environmental factors within a genetically susceptible host maneuver the innate and adaptive arms of the immune system toward recognition of autoantigens. This ultimately leads to joint destruction and clinical symptomatology. Despite the identification of a number of disease-susceptibility regions across the genome, RA's major genetic linkage remains with the major histocompatibility complex (MHC), which contains not only the key immune-response class I and class II genes but also a host of other loci, some with potential immunological relevance. Inside the MHC itself, the sole consistent RA association is that with HLA-DRB1, although this does not encode all MHC-related susceptibility. Indeed, in a set of Japanese patients with RA and a control group, we previously reported the presence of a second RA-susceptibility gene within the telomeric human leukocyte antigen (HLA) class III region. Using microsatellites, we narrowed the susceptibility region to 70 kb telomeric of the TNF cluster, known to harbor four expressed genes (I kappa BL, ATP6G, BAT1, and MICB). Here, using numerous single-nucleotide polymorphisms (SNPs) and insertion/deletion polymorphisms, we identify the second RA-susceptibility locus within the HLA region, as the T allele of SNP 96452 (T/A), in the promoter region (position -62) of the I kappa BL gene (P=.0062). This -62T/A SNP disrupts the putative binding motif for the transcriptional repressor, delta EF1, and hence may influence the transcription of I kappa BL, homologous to I kappa B alpha, the latter being a known inhibitor of NF kappa B, which is central to innate immunity. Therefore, the MHC may harbor RA genetic determinants affecting the innate and adaptive arms of the immune system.
Collapse
Affiliation(s)
- Koichi Okamoto
- Department of Molecular Life Science, Tokai University School of Medicine, Kanagawa, Japan; Fuji-Gotemba Research Laboratories, Chugai Pharmaceuticals, Shizuoka, Japan; Research and Development Center, Nisshinbo Industries, Chiba, Japan; Institute of Organ Transplants, Reconstructive Medicine and Tissue Engineering, and Department of Legal Medicine, Shinshu University School of Medicine, Nagano, Japan; Department of Molecular Pathogenesis, Division of Adult Disease, Medical Research Institute, Tokyo Medical and Dental University, Tokyo; and INSERM-CReS Centre de Recherche d’Immunologie et d’Hematologie, Strasbourg, France
| | - Satoshi Makino
- Department of Molecular Life Science, Tokai University School of Medicine, Kanagawa, Japan; Fuji-Gotemba Research Laboratories, Chugai Pharmaceuticals, Shizuoka, Japan; Research and Development Center, Nisshinbo Industries, Chiba, Japan; Institute of Organ Transplants, Reconstructive Medicine and Tissue Engineering, and Department of Legal Medicine, Shinshu University School of Medicine, Nagano, Japan; Department of Molecular Pathogenesis, Division of Adult Disease, Medical Research Institute, Tokyo Medical and Dental University, Tokyo; and INSERM-CReS Centre de Recherche d’Immunologie et d’Hematologie, Strasbourg, France
| | - Yoko Yoshikawa
- Department of Molecular Life Science, Tokai University School of Medicine, Kanagawa, Japan; Fuji-Gotemba Research Laboratories, Chugai Pharmaceuticals, Shizuoka, Japan; Research and Development Center, Nisshinbo Industries, Chiba, Japan; Institute of Organ Transplants, Reconstructive Medicine and Tissue Engineering, and Department of Legal Medicine, Shinshu University School of Medicine, Nagano, Japan; Department of Molecular Pathogenesis, Division of Adult Disease, Medical Research Institute, Tokyo Medical and Dental University, Tokyo; and INSERM-CReS Centre de Recherche d’Immunologie et d’Hematologie, Strasbourg, France
| | - Asumi Takaki
- Department of Molecular Life Science, Tokai University School of Medicine, Kanagawa, Japan; Fuji-Gotemba Research Laboratories, Chugai Pharmaceuticals, Shizuoka, Japan; Research and Development Center, Nisshinbo Industries, Chiba, Japan; Institute of Organ Transplants, Reconstructive Medicine and Tissue Engineering, and Department of Legal Medicine, Shinshu University School of Medicine, Nagano, Japan; Department of Molecular Pathogenesis, Division of Adult Disease, Medical Research Institute, Tokyo Medical and Dental University, Tokyo; and INSERM-CReS Centre de Recherche d’Immunologie et d’Hematologie, Strasbourg, France
| | - Yumie Nagatsuka
- Department of Molecular Life Science, Tokai University School of Medicine, Kanagawa, Japan; Fuji-Gotemba Research Laboratories, Chugai Pharmaceuticals, Shizuoka, Japan; Research and Development Center, Nisshinbo Industries, Chiba, Japan; Institute of Organ Transplants, Reconstructive Medicine and Tissue Engineering, and Department of Legal Medicine, Shinshu University School of Medicine, Nagano, Japan; Department of Molecular Pathogenesis, Division of Adult Disease, Medical Research Institute, Tokyo Medical and Dental University, Tokyo; and INSERM-CReS Centre de Recherche d’Immunologie et d’Hematologie, Strasbourg, France
| | - Masao Ota
- Department of Molecular Life Science, Tokai University School of Medicine, Kanagawa, Japan; Fuji-Gotemba Research Laboratories, Chugai Pharmaceuticals, Shizuoka, Japan; Research and Development Center, Nisshinbo Industries, Chiba, Japan; Institute of Organ Transplants, Reconstructive Medicine and Tissue Engineering, and Department of Legal Medicine, Shinshu University School of Medicine, Nagano, Japan; Department of Molecular Pathogenesis, Division of Adult Disease, Medical Research Institute, Tokyo Medical and Dental University, Tokyo; and INSERM-CReS Centre de Recherche d’Immunologie et d’Hematologie, Strasbourg, France
| | - Gen Tamiya
- Department of Molecular Life Science, Tokai University School of Medicine, Kanagawa, Japan; Fuji-Gotemba Research Laboratories, Chugai Pharmaceuticals, Shizuoka, Japan; Research and Development Center, Nisshinbo Industries, Chiba, Japan; Institute of Organ Transplants, Reconstructive Medicine and Tissue Engineering, and Department of Legal Medicine, Shinshu University School of Medicine, Nagano, Japan; Department of Molecular Pathogenesis, Division of Adult Disease, Medical Research Institute, Tokyo Medical and Dental University, Tokyo; and INSERM-CReS Centre de Recherche d’Immunologie et d’Hematologie, Strasbourg, France
| | - Akinori Kimura
- Department of Molecular Life Science, Tokai University School of Medicine, Kanagawa, Japan; Fuji-Gotemba Research Laboratories, Chugai Pharmaceuticals, Shizuoka, Japan; Research and Development Center, Nisshinbo Industries, Chiba, Japan; Institute of Organ Transplants, Reconstructive Medicine and Tissue Engineering, and Department of Legal Medicine, Shinshu University School of Medicine, Nagano, Japan; Department of Molecular Pathogenesis, Division of Adult Disease, Medical Research Institute, Tokyo Medical and Dental University, Tokyo; and INSERM-CReS Centre de Recherche d’Immunologie et d’Hematologie, Strasbourg, France
| | - Seiamak Bahram
- Department of Molecular Life Science, Tokai University School of Medicine, Kanagawa, Japan; Fuji-Gotemba Research Laboratories, Chugai Pharmaceuticals, Shizuoka, Japan; Research and Development Center, Nisshinbo Industries, Chiba, Japan; Institute of Organ Transplants, Reconstructive Medicine and Tissue Engineering, and Department of Legal Medicine, Shinshu University School of Medicine, Nagano, Japan; Department of Molecular Pathogenesis, Division of Adult Disease, Medical Research Institute, Tokyo Medical and Dental University, Tokyo; and INSERM-CReS Centre de Recherche d’Immunologie et d’Hematologie, Strasbourg, France
| | - Hidetoshi Inoko
- Department of Molecular Life Science, Tokai University School of Medicine, Kanagawa, Japan; Fuji-Gotemba Research Laboratories, Chugai Pharmaceuticals, Shizuoka, Japan; Research and Development Center, Nisshinbo Industries, Chiba, Japan; Institute of Organ Transplants, Reconstructive Medicine and Tissue Engineering, and Department of Legal Medicine, Shinshu University School of Medicine, Nagano, Japan; Department of Molecular Pathogenesis, Division of Adult Disease, Medical Research Institute, Tokyo Medical and Dental University, Tokyo; and INSERM-CReS Centre de Recherche d’Immunologie et d’Hematologie, Strasbourg, France
| |
Collapse
|
36
|
Smerdel A, Lie BA, Finholt C, Ploski R, Førre Ø, Undlien DE, Thorsby E. An additional susceptibility gene for juvenile idiopathic arthritis in the HLA class I region on several DR-DQ haplotypes. TISSUE ANTIGENS 2003; 61:80-4. [PMID: 12622778 DOI: 10.1034/j.1399-0039.2003.610107.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Juvenile idiopathic arthritis (JIA) is an HLA-associated rheumatic disease with onset in childhood. We recently reported that allele 5 at microsatellite D6S265 in the HLA class I region is associated with JIA, independent of linkage disequilibrium with the high risk DR8-DQ4 haplotype. In the present study, we investigated whether alleles at D6S265, or other markers in this region, also modify the risk for JIA on other haplotypes, i.e., DRB1*1301-DQB1*0603 or DRB1*1101/4-DQB1*0301. We observed a significant association with allele 6 at D6S265 on the DRB1*1301-DQB1*0603 haplotype. We also noted an association with allele 3 at D6S265, when carried on the DRB1*1101/4-DQB1*0301 haplotype. Our results further support an additional JIA susceptibility gene in the HLA class I region in linkage disequilibrium with alleles at D6S265.
Collapse
Affiliation(s)
- A Smerdel
- Institute of Immunology, Rikshospitalet University Hospital, Oslo, Norway.
| | | | | | | | | | | | | |
Collapse
|
37
|
Karplus TM, Jeronimo SMB, Chang H, Helms BK, Burns TL, Murray JC, Mitchell AA, Pugh EW, Braz RFS, Bezerra FL, Wilson ME. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun 2002; 70:6919-25. [PMID: 12438370 PMCID: PMC133071 DOI: 10.1128/iai.70.12.6919-6925.2002] [Citation(s) in RCA: 82] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2002] [Revised: 07/30/2002] [Accepted: 09/15/2002] [Indexed: 01/09/2023] Open
Abstract
A periurban outbreak of visceral leishmaniasis (VL) caused by the protozoan Leishmania chagasi is ongoing outside Natal, northeast Brazil. Manifestations range from asymptomatic infection to disseminated visceral disease. Literature reports suggest that both genetic and environmental factors influence the outcome of infection. Due to the association of the tumor necrosis factor (TNF) locus with other infectious diseases, we examined whether polymorphic alleles at this locus are associated with the outcome of L. chagasi infection. Neighborhoods with ongoing transmission were identified through patients admitted to local hospitals. Altogether, 1,024 individuals from 183 families were classified with the following disease phenotypes: (i) symptomatic VL, (ii) asymptomatic infection (positive delayed-type hypersensitivity [DTH+]), or (iii) no evidence of infection (DTH-). Genotypes were determined at a microsatellite marker (MSM) upstream of the TNFB gene encoding TNF-beta and at a restriction fragment length polymorphism (RFLP) at position -307 in the promoter of the TNFA gene encoding TNF-alpha. Analyses showed that the distribution of TNFA RFLP alleles (TNF1 and TNF2) and the TNF MSM alleles (TNFa1 to TNFa15) differed between individuals with VL and those with DTH+ phenotypes. TNF1 was transmitted more frequently than expected from heterozygous parents to DTH+ offspring (P = 0.0006), and haplotypes containing TNF2 were associated with symptomatic VL (P = 0.0265, transmission disequilibrium test). Resting serum TNF-alpha levels were higher in TNF1/2 heterozygotes than in TNF1/1 homozygotes (P < 0.05). These data led us to hypothesize that an individual's genotype at the TNF locus may be associated with whether he or she develops asymptomatic or symptomatic disease after L. chagasi infection. The results preliminarily suggest that this may be the case, and follow-up with larger populations is needed for verification.
Collapse
Affiliation(s)
- Theresa M Karplus
- Department of Internal Medicine, University of Iowa, Iowa City 52242, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Jawaheer D, Li W, Graham RR, Chen W, Damle A, Xiao X, Monteiro J, Khalili H, Lee A, Lundsten R, Begovich A, Bugawan T, Erlich H, Elder JT, Criswell LA, Seldin MF, Amos CI, Behrens TW, Gregersen PK. Dissecting the genetic complexity of the association between human leukocyte antigens and rheumatoid arthritis. Am J Hum Genet 2002; 71:585-94. [PMID: 12181776 PMCID: PMC449696 DOI: 10.1086/342407] [Citation(s) in RCA: 161] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2002] [Accepted: 06/14/2002] [Indexed: 11/03/2022] Open
Abstract
Rheumatoid arthritis (RA) is an inflammatory disease with a complex genetic component. An association between RA and the human leukocyte antigen (HLA) complex has long been observed in many different populations, and most studies have focused on a direct role for the HLA-DRB1 "shared epitope" in disease susceptibility. We have performed an extensive haplotype analysis, using 54 markers distributed across the entire HLA complex, in a set of 469 multicase families with RA. The results show that, in addition to associations with the DRB1 alleles, at least two additional genetic effects are present within the major histocompatibility complex. One of these lies within a 497-kb region in the central portion of the HLA complex, an interval that excludes DRB1. This genetic risk factor is present on a segment of a highly conserved ancestral A1-B8-DRB1*03 (8.1) haplotype. Additional risk genes may also be present in the HLA class I region in a subset of DRB1*0404 haplotypes. These data emphasize the importance of defining haplotypes when trying to understand the HLA associations with disease, and they clearly demonstrate that such associations with RA are complex and cannot be completely explained by the DRB1 locus.
Collapse
Affiliation(s)
- Damini Jawaheer
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Wentian Li
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Robert R. Graham
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Wei Chen
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Aarti Damle
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Xiangli Xiao
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Joanita Monteiro
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Houman Khalili
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Annette Lee
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Robert Lundsten
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Ann Begovich
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Teodorica Bugawan
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Henry Erlich
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - James T. Elder
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Lindsey A. Criswell
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Michael F. Seldin
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Christopher I. Amos
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Timothy W. Behrens
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| | - Peter K. Gregersen
- Center for Genomics and Human Genetics, North Shore–Long Island Jewish Research Institute, Manhasset, New York; Center for Immunology, University of Minnesota, Minneapolis; Departments of Epidemiology and Biomathematics, University of Texas, M. D. Anderson Cancer Center, Houston; Roche Molecular Systems, Berkeley, CA; Departments of Dermatology and Radiation Oncology, University of Michigan, Ann Arbor; The Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California at San Francisco, San Francisco; and Department of Biological Chemistry, University of California at Davis, Davis
| |
Collapse
|
39
|
Abstract
The data from the human genome project were published in 2001. Although this achievement will boost research in the genetics of rheumatoid arthritis (RA), most of the work is in progress. Three of the four consortia that are performing linkage studies to identify loci that are transmitted more often to patients than controls have published data on genome-wide searches in few families. Of all the possible candidate genes, the human leukocyte antigen (HLA) class II region was found in the pan-European and the US linkage studies, confirming the previous data from association studies that HLA class II alleles confer risk to RA. Although HLA as a risk factor for RA has been known for a long time, the mechanism by which HLA alleles affect disease risk are controversial. Several papers have been published recently that support the RA-protection hypothesis. Several candidate loci/genes have been suggested from association studies. However, these associations have not been reproduced by different groups in several different cohorts.
Collapse
Affiliation(s)
- Tom W J Huizinga
- Leiden University Medical Center, Department of Rheumatology, C4-R, PO Box 9600, 2300 RC Leiden, The Netherlands.
| |
Collapse
|
40
|
Buckner JH, Nepom GT. Genetics of rheumatoid arthritis: is there a scientific explanation for the human leukocyte antigen association? Curr Opin Rheumatol 2002; 14:254-9. [PMID: 11981323 DOI: 10.1097/00002281-200205000-00011] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Human leukocyte antigen genes associated with rheumatoid arthritis are commonly found in the unaffected population, implying that causal mechanisms of disease involve interactions between these genes and other factors. A variety of approaches-genetic, structural, and immunologic-are used to explore possible molecular interactions that may contribute to understanding the basis for this disease association. The specific relation between human leukocyte antigen-DR4 alleles and rheumatoid arthritis remains one of the strongest and most thoroughly studied examples of human leukocyte antigen risk genes among human autoimmune disorders.
Collapse
Affiliation(s)
- Jane H Buckner
- Benaroya Research Institute, Virginia Mason Research Center, Seattle, Washington 98101, USA.
| | | |
Collapse
|
41
|
Abstract
The investigation of genetic factors affecting the development or severity of rheumatoid arthritis may give new insights into the pathways involved in disease pathogenesis and lead to the identification of novel therapeutic targets. Recently, several novel approaches have been used in the attempt to unravel the complex association of rheumatoid arthritis with the human leukocyte antigen ( HLA ) gene region. It is clear that non-HLA genes are also involved in disease pathogenesis, and identifying them remains a challenge. In the past year, considerable headway has been made in this field, and some interesting strategies have been used. This review summarizes the results of many of the HLA and non-HLA studies and tries to draw lessons from the investigation of genetic susceptibility factors in other complex diseases.
Collapse
Affiliation(s)
- Anne Barton
- ARC Epidemiology Unit, University of Manchester, Manchester, UK.
| | | |
Collapse
|
42
|
Matthews VB, Witt CS, French MAH, Machulla HKG, De la Concha EG, Cheong KY, Vigil P, Hollingsworth PN, Warr KJ, Christiansen FT, Price P. Central MHC genes affect IgA levels in the human: reciprocal effects in IgA deficiency and IgA nephropathy. Hum Immunol 2002; 63:424-33. [PMID: 11975987 DOI: 10.1016/s0198-8859(02)00383-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
This study investigates the hypothesis that alternative alleles of one or more genes in the central major histocompatibility complex (MHC) predispose carriers to IgA deficiency (IgAD) or IgA Nephropathy (IgAN). Australian caucasian IgAD, IgAN patients, and controls were typed at HLA loci, single nucleotide polymorphisms, and microsatellites in the MHC. Alleles of the D6S273 microsatellite exhibited strong associations with IgAD and IgAN. D6S273*129 and *139 were more frequent in IgAD and less frequent in IgAN patients than controls. The reverse was true for D6S273*133 and *131. Alleles of other microsatellites exhibited weak associations with IgAD or IgAN. D6S273*129 is found on the 65.1 ancestral haplotype [HLA-B14(65),DR1], which has been reported to be increased in IgAD, but the majority of IgAD patients with D6S273*129 did not have other alleles of the haplotype. D6S273*139 is characteristic of the 8.1 ancestral haplotype (HLA-A1,B8,DR3), which was common in IgAD and rare in IgAN patients. Further studies of the 8.1 haplotype in Australian, German and Spanish caucasian subjects revealed that HLA-DR3, in the absence of -B8, is not associated with IgAD. However -B8 is associated with IgAD in the absence of -DR3, consistent with a susceptibility locus in the central MHC. Provisional mapping within this region is discussed.
Collapse
Affiliation(s)
- Vance B Matthews
- Department of Clinical Immunology and Biochemical Genetics, Royal Perth Hospital, Australia.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Rodríguez MR, González-Escribano MF, Aguilar F, Valenzuela A, García A, Núñez-Roldán A. Association of NRAMP1 promoter gene polymorphism with the susceptibility and radiological severity of rheumatoid arthritis. TISSUE ANTIGENS 2002; 59:311-5. [PMID: 12135431 DOI: 10.1034/j.1399-0039.2002.590410.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The natural resistant-associated macrophage protein 1 (NRAMP1) has been proposed as a candidate gene for the susceptibility to autoimmune diseases. In this study, the possible role of the functional polymorphism located at the promoter region of NRAMP1 gene in the susceptibility and clinical outcome of rheumatoid arthritis (RA) was investigated. A total of 141 Spanish RA patients and 194 controls previously typed for HLA-DRB1* were genotyped for the NRAMP1 polymorphism. No significant differences in the distribution of frequencies among RA patients and controls were observed. Nevertheless, when patients and controls were stratified according to their HLA shared epitope (SE) status, an increase of 2/2 genotype among SE-negative (SE-) patients with respect to SE- controls was observed (23% vs 7%, OR = 3.74, 95% CI 1.31-10.72). In addition, the possible role of this polymorphism in the clinical course of RA was investigated in a subgroup of 82 patients who were prospectively followed during a mean of 9 years. After follow-up, an increase of patients with the homozygous 2/2 genotype was detected among those with severe small joint radiological involvement: 73% of patients 2/2 had a severe form in contrast to 37% of patients with the genotype 2/3 and 30% of patients bearing 3/3 OR = 5.45, 95% CI 1.14-34.24). In conclusion, NRAMP1 gene promoter polymorphism could influence the radiological severity of rheumatoid arthritis and disease susceptibility, particularly in individuals lacking HLA-linked risk factors.
Collapse
Affiliation(s)
- M R Rodríguez
- Hospital Universitario Virgen del Rocío, Servicio Andaluz de Salud, Sevilla, Spain
| | | | | | | | | | | |
Collapse
|
44
|
Jawaheer D, Gregersen PK. The search for rheumatoid arthritis susceptibility genes: a call for global collaboration. ARTHRITIS AND RHEUMATISM 2002; 46:582-4. [PMID: 11920392 DOI: 10.1002/art.10169] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
45
|
Wassmuth R, Wagner U. Prognostic use of human leukocyte antigen genotyping for rheumatoid arthritis susceptibility, disease course, and clinical stratification. Rheum Dis Clin North Am 2002; 28:17-37. [PMID: 11840696 DOI: 10.1016/s0889-857x(03)00067-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
HLA markers of the class II region are important for determination of the predisposition to RA, clinical manifestations, and rate of progression of joint destruction in this autoimmune disease. Furthermore, evidence emerges indicating that HLA markers also have an impact on treatment outcome in RA. Currently, several immunopathogenetic models of HLA-dependent influences in RA are under debate. These models insufficiently explain the graded influence of HLA-DR and HLA-DQ on manifestation and joint destruction, however. Currently, there is not enough evidence to unequivocally identify a primary susceptibility locus or to pinpoint the HLA-dependent mechanism in RA. Overall, the influence of HLA class II markers on disease susceptibility is rather restricted, and, in turn, their utility in establishing the diagnosis of RA is of limited use. Although relative risks are higher for the association of particular genotypes with extra-articular forms of RA, HLA genotyping may not contribute to prognostication in individual patients but may aid in disease stratification. In contrast, HLA genotyping in early RA, particularly when combined with the determination of RFs and determination of the presence of bony erosions, is of value to identify patients at risk for poor outcome. In turn, these patients may benefit from early aggressive therapy, and HLA genotyping should be useful to aid in risk stratification in patients and thus helpful for the choice of treatment. Lastly, disease and risk stratification based on HLA markers along with the elucidation of HLA-dependent mechanisms may facilitate the development of specific immunotherapy modalities.
Collapse
Affiliation(s)
- Ralf Wassmuth
- Institute for Transplantation Diagnostics and Cell Therapeutics, Duesseldorf University Medical Center, University of Duesseldorf, Duesseldorf, Germany.
| | | |
Collapse
|
46
|
Moxley G, Posthuma D, Carlson P, Estrada E, Han J, Benson LL, Neale MC. Sexual dimorphism in innate immunity. ARTHRITIS AND RHEUMATISM 2002; 46:250-8. [PMID: 11817599 DOI: 10.1002/1529-0131(200201)46:1<250::aid-art10064>3.0.co;2-t] [Citation(s) in RCA: 83] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
OBJECTIVE To establish whether variation in innate immunity, as measured by the level of tumor necrosis factor (TNF) in lipopolysaccharide (LPS)-stimulated whole-blood culture, is related to sex or HLA. METHODS Normal volunteers (72 women, 159 men) completed questionnaires and donated peripheral blood specimens. Blood samples were exposed to LPS in a 4-hour in vitro culture, and supernatants were then tested by sandwich-type immunoassay measuring TNF levels. Statistical techniques included multivariate analysis and maximal-likelihood modeling of allelic effects. RESULTS Both male and female groups showed substantial within-group variation (coefficient of variation 59.1% for women, 40.3% for men). However, the mean +/- SD LPS-stimulated TNF level in the female group was nearly 30% lower than in the male group (1,556+/-919 pg/ml versus 2,203+/-889 pg/ml; P < 0.0001, unadjusted for covariates). Sex was independent of any microsatellite marker allele of TNF (covariate-adjusted increment of 785 pg/ml from female to male sex; P < 0.0001). In multivariate modeling of the female group, the LPS-stimulated TNF level was not independently influenced by menstrual cycle phase, oral contraceptive use, or plasma estradiol level. Allelic modeling showed that significant TNFab microsatellite allelic effects existed (P = 0.002 versus model omitting allelic effects). The female group showed a significantly downward deviation from mean TNF level with TNFa4b5 (-903 pg/ml deviation from the overall mean) and an upward deviation with TNFa10b4 (598 pg/ml). The male group showed significantly higher-than-mean levels with TNFa1b5 (909 pg/ml), TNFa5b7 (1,191 pg/ml), and TNFa6b5 (332 pg/ml). Thus, the two sex groups differed in which of their TNFab marker alleles showed significant deviations from the overall mean. CONCLUSION Female subjects have a nearly 30% lower innate immune response, stemming largely from influence independent of the HLA-region TNF locus and without further independent variation stemming from plasma estrogen level.
Collapse
|
47
|
Mattey D. Extended HLA haplotypes and RA susceptibility. Arthritis Res Ther 2001. [DOI: 10.1186/ar-2001-68101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
48
|
Cheong KY, Allcock RJ, Eerligh P, Witt CS, Christiansen FT, McCann V, Price P. Localization of central MHC genes influencing type I diabetes. Hum Immunol 2001; 62:1363-70. [PMID: 11756005 DOI: 10.1016/s0198-8859(01)00351-2] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The contribution of MHC class II haplotypes to susceptibility to type I diabetes has been clearly established, and interest has now focused on the effects of additional genes in the MHC region. We have investigated the central MHC alleles on 8.1 ancestral haplotype (HLA-A1, B8, DR3, DQ2), as it is well conserved in Caucasian populations. The HLA-DR3-DQ2 genotype is a recognized risk factor for type I diabetes. Single nucleotide polymorphisms and microsatellites in the MHC were used to map segments of the 8.1 ancestral haplotype carried by type I diabetic and control subjects expressing either HLA-B8 or DR3, but not both these markers. In this way we controlled for the diabetogenic effect of carriage of DR3. Alleles of the 8.1 ancestral haplotype between TNFA-308/D6STNFa and HLA-B were carried with significantly greater frequency in B8(-), DR3(+) type I diabetic patients compared with B8(-), DR3(+) controls. This interval was marked by a BAT1 gene polymorphism and a MIB microsatellite allele.
Collapse
Affiliation(s)
- K Y Cheong
- Department of Clinical Immunology and Biochemical Genetics, Royal Perth Hospital, Perth, WA, Australia.
| | | | | | | | | | | | | |
Collapse
|
49
|
van der Linden MW, van der Slik AR, Zanelli E, Giphart MJ, Pieterman E, Schreuder GM, Westendorp RG, Huizinga TW. Six microsatellite markers on the short arm of chromosome 6 in relation to HLA-DR3 and TNF-308A in systemic lupus erythematosus. Genes Immun 2001; 2:373-80. [PMID: 11704803 DOI: 10.1038/sj.gene.6363794] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2001] [Revised: 08/06/2001] [Accepted: 08/06/2001] [Indexed: 12/22/2022]
Abstract
Differences in allelic distribution at loci surrounding the human HLA-DRB1 and tumor necrosis factor (TNF) genes have been observed in association with systemic lupus erythematosus (SLE). We investigated whether the association of HLA-DRB1*0301 (HLA-DR3) and TNF-308A with SLE could be attributed to polymorphic markers in the chromosomal region encompassed by HLA-DRB1 and HLA-C. Ninety-one consecutive Caucasian patients with SLE and 253 controls (organ donors) were typed for HLA-DRB1, microsatellites D6S1014, D6S273, TNFa, MIB, C1_2_5, and C1_3_2 and the single nucleotide polymorphism at position -308 in the promoter of TNF. The independent contribution of alleles to disease susceptibility was estimated by cross-tabulation and multivariate logistic regression. Possession of TNF-308A was associated with susceptibility to SLE (odds ratio [95% confidence interval], 3.70 [2.24-6.11]). This remained present after stratification on possession of HLA-DR3 (pooled odds ratio, 2.53 [1.37-4.70]). Stratification revealed a possible association of possession of C1_2_5*192 with protection from SLE beyond the effects of HLA-DR3 and TNF-308A. A gene dosage effect was observed for -308A only (homozygotes, 7.75 [3.01-20.0], heterozygotes, 3.15 [1.85-5.37]). In multivariate analysis, possession of HLA-DR3, TNF-308A, and C1_2_5*192 remained independently associated with susceptibility to SLE (2.58 [1.29-5.18], 2.76 [1.43-5.31], and 0.26 [0.10-0.66], respectively). The association of possession of TNF-308A with susceptibility to SLE cannot be attributed to linkage to HLA-DR3 alone, nor to other polymorphic markers in the vicinity of the TNF gene. Further loci that are independently associated with SLE might be in the vicinity of marker C1_2_5.
Collapse
Affiliation(s)
- M W van der Linden
- Department of Clinical Epidemiology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
Narcolepsy was first shown to be tightly associated with HLA-DR2 and DQ1 in 1983, suggesting a possible autoimmune mechanism. Early investigations failed to demonstrate this hypothesis, postulating that HLA-DR2 was only a linkage marker for another, unknown narcolepsy-causing gene. The autoimmune hypothesis is now being re-evaluated under the light of recent results. Like many other autoimmune disorders, narcolepsy usually starts during adolescence, is human leukocyte antigen (HLA)-associated, multigenic and environmentally influenced. Furthermore, HLA-association studies indicated a primary HLA-DQ effect with complex HLA class II allele interactions and a partial contribution of HLA to overall genetic susceptibility. Finally, recent result suggests that human narcolepsy is associated with the destruction of a small number of hypothalamic neurons containing the peptide hypocretins (orexins). This data is consistent with an immune destruction of hypocretin-containing cells as the most common etiology for human narcolepsy.
Collapse
Affiliation(s)
- L Lin
- Department of Psychiatry and Behavioral Sciences, Stanford Center for Narcolepsy, Stanford University Medical Center, 1201 Welch Road, P-114, Palo Alto, CA 94305-5485, USA
| | | | | |
Collapse
|